LOS ANGELES (September 8, 2015) – Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (Ritter), a pharmaceutical company developing novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, today announced that the Company’s Chief Executive Officer, Michael Step, will participate in the 3rd Microbiome R&D Business Collaboration Forum to be held September 10-11, 2015 in San Diego, CA.
Mr. Step will present an overview of RP-G28, Ritter’s lead product candidate which has the potential to become the first FDA-approved drug for the treatment of lactose intolerance. Presentation details are as follows:
Date/Time: Thursday, September 10 at 5:20pm PT
Presentation Title: Impact of RP-G28 on the Human Microbiome and Treating the Symptoms of Lactose Intolerance
A copy of the presentation will be available on the company’s website at www.ritterpharma.com.
In addition, Mr. Step will take part in a panel discussion of experts entitled “How to Foster the Growth of Microbiome Therapeutics” which will focus on the current landscape of pharma with regards to the microbiome, areas of focus and future development, and in-licensing and investment opportunities.
About Ritter Pharmaceuticals
Ritter Pharmaceuticals, Inc. develops novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Ritter Pharma is advancing human gut health research by exploring the metabolic capacity of gut microbiota, and translating the functionality of these microbiome modulators into safe and effective applications. The company’s lead drug candidate, RP-G28, has the potential to become the first FDA-approved drug for lactose intolerance, a condition that affects more than one billion people worldwide.